Menu

Sanctioned Psychiatrist Off Restriction

Charles Nemeroff, who was barred from receiving grants for 2 years in 2008, snags $401K from the NIH to study PTSD.

Aug 14, 2012
Jef Akst

In December 2008, psychiatrist Charles Nemeroff, then at Emory University, was sanctioned for not disclosing more than $1 million from drug companies to promote their products in academic publications. His punishment: Emory barred him from receiving grants for 2 years. But those 2 years have come and gone, and in May, the National Institutes of Health (NIH) awarded Nemeroff, now at the University of Miami, a 5-year, $401,675-a-year grant to study posttraumatic stress disorder.

Shortly after the grant was announced, however, Senator Charles Grassley (R-IA), an activist for public disclosure of financial relationships in the biomedical fields, wrote a letter to the NIH questioning the decision. “Please explain how the NIH arrived at this decision to award Dr. Nemeroff despite past ethical problems,” Grassley wrote. “Although NIH has recently revamped its conflict of interest guidelines, this decision risks sending the wrong message to physicians seeking or performing federally funded research.” Furthermore, he noted, the Department of Health and Human Services’s Office of Inspector General (OIG) and the Department of Justice (DOJ) have been collaborating on an investigation of Nemeroff, and the results of that query have yet to be released.

Earlier this month, NIH Deputy Director Lawrence Tabak responded to Grassley, the blog Pharmalot reported. He explained that peer reviewers weren't told about the OIG and DOJ investigations because they are confidential. "Absent any finding by the OIG or other actionable grounds at this time to exclude Dr. Nemeroff, the NIH followed standard procedures," Tabak wrote. In addition, the NIH specifically asked the University of Miami about potential conflicts of interest, noted that the research does not involve the testing of any drugs, and stated that a reviewer that used to work with Nemeroff (Thomas Insel, director of the National Institute of Mental Health) recused himself from the review process. "I want to assure you that all procedures have been followed carefully in the process of awarding this specific grant to the University of Miami," Tabak wrote.

(Hat tip to ScienceInsider.)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.